Jin Rong Jie·2026-02-10 09:04Core Insights - The Chinese biopharmaceutical industry is at a pivotal moment as it transitions from "scale and speed" to "quality and value" during the end of the 14th Five-Year Plan and the beginning of the 15th Five-Year Plan [1][3] - The company emphasizes the importance of innovation, dual-track development, and value orientation to navigate the challenges and opportunities in 2026 [1][4] Group 1: Industry Transition - The industry is experiencing a transformation focused on quality and value, moving away from previous growth models based on scale and speed [1][3] - The company aims to address the challenges of homogenization and competition by focusing on original innovation and differentiated strategies [3][4] Group 2: Globalization and Market Expansion - The company has established a global commercialization network covering over 80 countries and regions, with products launched in 40 international markets [2] - The strategy includes enhancing local patient access while expanding global partnerships to overcome international market entry barriers [4] Group 3: Innovation and Technology - The company is committed to deepening its innovation in the field of tumor immunotherapy, particularly in addressing PD-(L)1 inhibitor resistance [3] - AI technology is being leveraged to optimize operational efficiency and enhance quality, aligning with the industry's focus on sustainable development [4]